Voiant is the industry leading AI-based clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. Voiant combines leadership in artificial intelligence and visionary computing, key opinion leaders for strategic therapeutic areas alignment, and clinical research experts to deliver operational excellence and consistent execution – providing the shortest path to the highest quality imaging data for clinical trials. Voiant has interpreted +1 billion images from over 700 global clinical trials, aiding numerous biopharmaceutical companies bringing new treatments to patients across oncology, respiratory, ophthalmology, cardiovascular, gastrointestinal, and liver disease domains. Voiant Hub is our built for purpose AI-powered platform, enabling us to manage the entire clinical imaging process while providing site management, as well as full transparency to sponsors every step of the way from image upload, quality control, read & analysis to delivering high quality clinical imaging endpoints.
United Therapeutics
Stop by and see us at Booth 2527 to check out our immersive Vision Pro virtual reality experience! Founded by CEO Martine Rothblatt to discover a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases. Enabling remote monitoring of lung health, Strados Labs’ RESP Biosensor allows clinicians to continuously measure patients’ lung sounds such as cough and wheeze that can indicate an exacerbation or reduced quality of life. The technology is used to assist drug developers in demonstrating treatment efficacy in clinical trials and to support clinicians in disease surveillance and management. The RESP Biosensor is FDA-cleared, CE marked and HIPAA compliant, backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.